KR101308865B1 - 유아 산통을 감소시키기 위한 선별된 유산균의 용도 - Google Patents
유아 산통을 감소시키기 위한 선별된 유산균의 용도 Download PDFInfo
- Publication number
- KR101308865B1 KR101308865B1 KR1020107012584A KR20107012584A KR101308865B1 KR 101308865 B1 KR101308865 B1 KR 101308865B1 KR 1020107012584 A KR1020107012584 A KR 1020107012584A KR 20107012584 A KR20107012584 A KR 20107012584A KR 101308865 B1 KR101308865 B1 KR 101308865B1
- Authority
- KR
- South Korea
- Prior art keywords
- colic
- lactobacillus
- cells
- strains
- infants
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010021746 Infantile colic Diseases 0.000 title claims abstract description 36
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims abstract description 20
- 241000894006 Bacteria Species 0.000 title claims abstract description 14
- 235000014655 lactic acid Nutrition 0.000 title claims abstract description 10
- 239000004310 lactic acid Substances 0.000 title claims abstract description 10
- 208000002881 Colic Diseases 0.000 title claims description 71
- 102000003814 Interleukin-10 Human genes 0.000 claims abstract description 29
- 108090000174 Interleukin-10 Proteins 0.000 claims abstract description 29
- 238000004519 manufacturing process Methods 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 17
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 45
- 241000186660 Lactobacillus Species 0.000 claims description 25
- 210000004443 dendritic cell Anatomy 0.000 claims description 25
- 229940039696 lactobacillus Drugs 0.000 claims description 21
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 11
- 238000011161 development Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 7
- 210000001616 monocyte Anatomy 0.000 claims description 7
- 230000014509 gene expression Effects 0.000 claims description 5
- 210000003289 regulatory T cell Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 25
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 abstract description 9
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 abstract description 9
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 abstract description 9
- 230000035755 proliferation Effects 0.000 abstract description 6
- 230000002265 prevention Effects 0.000 abstract description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 53
- 210000004027 cell Anatomy 0.000 description 30
- 239000006041 probiotic Substances 0.000 description 20
- 235000018291 probiotics Nutrition 0.000 description 20
- 206010011469 Crying Diseases 0.000 description 17
- 102000004127 Cytokines Human genes 0.000 description 15
- 108090000695 Cytokines Proteins 0.000 description 15
- 230000000968 intestinal effect Effects 0.000 description 15
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 229940083037 simethicone Drugs 0.000 description 12
- 102000002689 Toll-like receptor Human genes 0.000 description 11
- 108020000411 Toll-like receptor Proteins 0.000 description 11
- 230000035800 maturation Effects 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 102000013462 Interleukin-12 Human genes 0.000 description 10
- 108010065805 Interleukin-12 Proteins 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 10
- 210000001035 gastrointestinal tract Anatomy 0.000 description 10
- 230000000529 probiotic effect Effects 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 8
- 230000031261 interleukin-10 production Effects 0.000 description 8
- 206010003645 Atopy Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 210000000987 immune system Anatomy 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 208000018522 Gastrointestinal disease Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 244000199866 Lactobacillus casei Species 0.000 description 5
- 208000026935 allergic disease Diseases 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 208000010643 digestive system disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 208000018685 gastrointestinal system disease Diseases 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 208000012868 Overgrowth Diseases 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 description 4
- CURUTKGFNZGFSE-UHFFFAOYSA-N dicyclomine Chemical compound C1CCCCC1C1(C(=O)OCCN(CC)CC)CCCCC1 CURUTKGFNZGFSE-UHFFFAOYSA-N 0.000 description 4
- 229960002777 dicycloverine Drugs 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 235000013350 formula milk Nutrition 0.000 description 4
- 244000005709 gut microbiome Species 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 230000002519 immonomodulatory effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 244000005706 microflora Species 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000007115 recruitment Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 235000013958 Lactobacillus casei Nutrition 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 108010046377 Whey Proteins Proteins 0.000 description 3
- 102000007544 Whey Proteins Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 235000008452 baby food Nutrition 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000001332 colony forming effect Effects 0.000 description 3
- 230000010243 gut motility Effects 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 230000000774 hypoallergenic effect Effects 0.000 description 3
- 210000003405 ileum Anatomy 0.000 description 3
- 230000004609 intestinal homeostasis Effects 0.000 description 3
- 229940017800 lactobacillus casei Drugs 0.000 description 3
- 230000004899 motility Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 244000005714 skin microbiome Species 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- AKXKFZDCRYJKTF-UHFFFAOYSA-N 3-Hydroxypropionaldehyde Chemical compound OCCC=O AKXKFZDCRYJKTF-UHFFFAOYSA-N 0.000 description 2
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 2
- 208000012657 Atopic disease Diseases 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 208000004262 Food Hypersensitivity Diseases 0.000 description 2
- 206010016946 Food allergy Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 240000006024 Lactobacillus plantarum Species 0.000 description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 101800002372 Motilin Proteins 0.000 description 2
- 102000002419 Motilin Human genes 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 2
- 206010030216 Oesophagitis Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001078 anti-cholinergic effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 208000006881 esophagitis Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000006651 lactation Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000820 nonprescription drug Substances 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 235000021119 whey protein Nutrition 0.000 description 2
- OTHYPAMNTUGKDK-UHFFFAOYSA-N (3-acetylphenyl) acetate Chemical compound CC(=O)OC1=CC=CC(C(C)=O)=C1 OTHYPAMNTUGKDK-UHFFFAOYSA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000590988 Danainae Species 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000027776 Extrapyramidal disease Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 206010061991 Grimacing Diseases 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 208000035756 Infantile asthma Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 241001468157 Lactobacillus johnsonii Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- 208000027419 Muscular hypotonia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000029726 Neurodevelopmental disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 description 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229940092732 belladonna alkaloid Drugs 0.000 description 1
- 229940088007 benadryl Drugs 0.000 description 1
- 229940071604 biogaia Drugs 0.000 description 1
- GERIGMSHTUAXSI-UHFFFAOYSA-N bis(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 4-phenyl-2,3-dihydro-1h-naphthalene-1,4-dicarboxylate Chemical compound CN1C(C2)CCC1CC2OC(=O)C(C1=CC=CC=C11)CCC1(C(=O)OC1CC2CCC(N2C)C1)C1=CC=CC=C1 GERIGMSHTUAXSI-UHFFFAOYSA-N 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 231100000670 co-carcinogen Toxicity 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000007382 columbia agar Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 235000020205 cow's milk formula Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 235000021045 dietary change Nutrition 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000006052 feed supplement Substances 0.000 description 1
- 238000003872 feeding technique Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000004578 fetal growth Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 229960001550 hyoscyamine sulfate Drugs 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 210000005204 intestinal dendritic cell Anatomy 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000020214 lactose-free milk formula Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 229940100466 mylicon Drugs 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 235000020939 nutritional additive Nutrition 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940069533 paregoric Drugs 0.000 description 1
- 239000008414 paregoric Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/853—Lactobacillus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/446,628 | 2006-06-05 | ||
| US11/446,628 US7374924B2 (en) | 2006-06-05 | 2006-06-05 | Use of selected lactic acid bacteria for reducing infantile colic |
| PCT/SE2007/050371 WO2007142596A1 (en) | 2006-06-05 | 2007-05-30 | Use of selected lactic acid bacteria for reducing infantile colic |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020087026182A Division KR101030661B1 (ko) | 2006-06-05 | 2007-05-30 | 유아 산통을 감소시키기 위한 선별된 유산균의 용도 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20100080565A KR20100080565A (ko) | 2010-07-08 |
| KR101308865B1 true KR101308865B1 (ko) | 2013-09-17 |
Family
ID=38790468
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020107012584A Active KR101308865B1 (ko) | 2006-06-05 | 2007-05-30 | 유아 산통을 감소시키기 위한 선별된 유산균의 용도 |
| KR1020087026182A Active KR101030661B1 (ko) | 2006-06-05 | 2007-05-30 | 유아 산통을 감소시키기 위한 선별된 유산균의 용도 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020087026182A Active KR101030661B1 (ko) | 2006-06-05 | 2007-05-30 | 유아 산통을 감소시키기 위한 선별된 유산균의 용도 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US7374924B2 (enExample) |
| EP (1) | EP2040722B1 (enExample) |
| JP (3) | JP4520531B2 (enExample) |
| KR (2) | KR101308865B1 (enExample) |
| CN (2) | CN102488717B (enExample) |
| AU (2) | AU2007200434B2 (enExample) |
| BR (1) | BRPI0710944B8 (enExample) |
| CA (1) | CA2650546C (enExample) |
| DK (1) | DK2040722T3 (enExample) |
| GE (1) | GEP20125480B (enExample) |
| HU (1) | HUE026416T2 (enExample) |
| IL (1) | IL194779A0 (enExample) |
| MX (1) | MX2008014869A (enExample) |
| MY (1) | MY162708A (enExample) |
| NZ (2) | NZ596788A (enExample) |
| RU (1) | RU2435844C2 (enExample) |
| SI (1) | SI2040722T1 (enExample) |
| UA (1) | UA93911C2 (enExample) |
| WO (1) | WO2007142596A1 (enExample) |
| ZA (1) | ZA200809531B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7374924B2 (en) * | 2006-06-05 | 2008-05-20 | Biogaia Ab | Use of selected lactic acid bacteria for reducing infantile colic |
| EP2265135B1 (en) * | 2008-03-14 | 2017-12-20 | Nestec S.A. | Synbiotic mixture |
| AU2014221272B2 (en) * | 2008-11-03 | 2016-01-21 | Société des Produits Nestlé S.A. | A nutritional composition comprising probiotics and improving sleep patterns |
| RU2517616C2 (ru) * | 2008-11-03 | 2014-05-27 | Нестек С.А. | Питательная композиция, включающая пробиотики и улучшающая характер сна |
| US20110104327A1 (en) * | 2009-04-23 | 2011-05-05 | Bacterfield International S.A. | Probiotic pet food |
| SG177541A1 (en) | 2009-07-31 | 2012-02-28 | Nestec Sa | Nutritional composition for breast-fed infants or pets with probiotics and selected nutrients |
| NL2004101C2 (en) * | 2010-01-15 | 2011-07-18 | Friesland Brands Bv | Ruminant il-10 and use in modulating immune response. |
| IT1401460B1 (it) * | 2010-06-11 | 2013-07-26 | Probiotical Spa | "ceppi di batteri probiotici produttori di vitamina b12" |
| KR101706100B1 (ko) * | 2011-12-15 | 2017-02-15 | 삼성전자주식회사 | 성형한계선도 획득용 시험장치 |
| EP2609813A1 (en) * | 2011-12-30 | 2013-07-03 | Nestec S.A. | Lactobacillus reuteri DSM 17938 for the development of the enteric nervous system |
| UA118339C2 (uk) * | 2012-09-03 | 2019-01-10 | Біогайа Аб | Бактеріальний штам lactobacillus gasseri для лікування порушення моторики кишечнику (варіанти) |
| US11179427B2 (en) | 2013-01-21 | 2021-11-23 | Eth Zurich | Baby food composition comprising viable propionic acid-producing bacteria |
| WO2015018883A2 (en) * | 2013-08-09 | 2015-02-12 | Ab-Biotics, S.A. | Probiotic for infantile excessive crying |
| AU2015209763B2 (en) | 2014-01-23 | 2020-12-24 | Biogaia Ab | Selection of agents modulating gastrointestinal pain |
| CN106794207A (zh) * | 2014-10-29 | 2017-05-31 | 雀巢产品技术援助有限公司 | 使用罗伊氏乳杆菌在生命早期恢复微生物群生态失调 |
| EP3294308A4 (en) | 2015-05-14 | 2019-03-06 | University of Puerto Rico | PROCESS FOR RECOVERING THE BIOZOOSE OF NEWBORN |
| JP6529835B2 (ja) * | 2015-06-23 | 2019-06-12 | 株式会社フィス | 樹状細胞活性化剤 |
| CN105219683B (zh) * | 2015-11-04 | 2018-03-13 | 广东省农业科学院动物科学研究所 | 一株具有益生特征的罗伊氏乳杆菌菌株及其应用 |
| WO2017117142A1 (en) | 2015-12-28 | 2017-07-06 | New York University | Device and method of restoring microbiota of newborns |
| CN106497840B (zh) * | 2016-11-07 | 2019-06-21 | 江南大学 | 一种定向分离免疫调节性肠道乳杆菌的方法 |
| CN117487686A (zh) * | 2018-07-24 | 2024-02-02 | 生命大地女神有限公司 | 选择和使用褪黑素支持细菌以减少婴儿绞痛 |
| MX2020014222A (es) * | 2018-07-24 | 2021-03-09 | Biogaia Ab | Metodos terapeuticos que utilizan cepas bacterianas las cuales son capaces de aumentar los niveles de adenosina. |
| SG11202110355RA (en) * | 2019-04-17 | 2021-11-29 | Biogaia Ab | Therapeutic microvesicles of probiotic bacteria |
| US20240165171A1 (en) * | 2021-03-26 | 2024-05-23 | Seoul National University R&Db Foundation | Composition for enhancing physiological efficacy of lactic acid bacteria |
| CN117925484B (zh) * | 2024-03-19 | 2024-07-09 | 山东中科嘉亿生物工程有限公司 | 一株改善睡眠呼吸暂停的罗伊氏粘液乳杆菌jylb-101及其产品和应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040185032A1 (en) | 2003-03-18 | 2004-09-23 | David Burrell | Compositions and methods for treating colic |
| US20050271641A1 (en) | 2004-06-03 | 2005-12-08 | Bengt Bjorksten | Method for improved breast milk feeding to reduce the risk of allergy |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4518696A (en) | 1983-01-11 | 1985-05-21 | Chr. Hansen's Laboratory, Inc. | Stabilized liquid bacterial suspension for oral administration to animals |
| US5413960A (en) | 1987-05-01 | 1995-05-09 | Biogaia Ab | Antibiotic reuterin |
| US5458875A (en) | 1990-06-15 | 1995-10-17 | Biogaia Ab | In ovo method for delivering Lactobacillus reuteri to the gastrointestinal tract of poultry |
| US5534253A (en) | 1995-06-07 | 1996-07-09 | Biogaia Ab | Method of treating enteropathogenic bacterial infections in poultry |
| AU718040B2 (en) | 1995-12-21 | 2000-04-06 | Abbott Laboratories | Use of lactobacillus reuteri to inhibit cryptosporidiosis in mammals |
| US5837238A (en) | 1996-06-05 | 1998-11-17 | Biogaia Biologics Ab | Treatment of diarrhea |
| US5800813A (en) | 1996-11-12 | 1998-09-01 | Biogaia Biologics Ab | Treatment of cryptosporidium infections |
| KR19990024297A (ko) | 1997-08-07 | 1999-04-06 | 오종석 | 인체 구강내 치태형성을 억제하는 신규한 유산균 |
| US6100388A (en) | 1998-03-16 | 2000-08-08 | Biogaia Biologies Ab | Lactobacilli harboring aggregation gene as a vaccine delivery vehicle |
| EP1034788A1 (en) | 1999-03-11 | 2000-09-13 | Société des Produits Nestlé S.A. | Lactic acid bacteria strains capable of preventing diarrhea |
| EP1344458A1 (en) * | 2002-03-12 | 2003-09-17 | Société des Produits Nestlé S.A. | Probiotic delivery system |
| EP1384483A1 (en) * | 2002-07-23 | 2004-01-28 | Nestec S.A. | Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function |
| US7105336B2 (en) | 2002-10-07 | 2006-09-12 | Biogaia Ab | Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter |
| EP1567018B1 (en) * | 2002-10-18 | 2009-07-01 | Biogaia Ab | Method of improving immune function in mammals using lactobacillus reuteri strains |
| US20040208863A1 (en) | 2003-01-30 | 2004-10-21 | James Versalovic | Anti-inflammatory activity from lactic acid bacteria |
| EP1638414B1 (en) * | 2003-06-23 | 2009-06-17 | Nestec S.A. | Infant or follow-on formula |
| US20060251634A1 (en) * | 2005-05-06 | 2006-11-09 | Ho-Jin Kang | Method of improving immune function in mammals using lactobacillus strains with certain lipids |
| US8603460B2 (en) * | 2006-06-05 | 2013-12-10 | Brogaia AB | Method of making a Lactobacillus reuteri with increased acid tolerance |
| US7374924B2 (en) * | 2006-06-05 | 2008-05-20 | Biogaia Ab | Use of selected lactic acid bacteria for reducing infantile colic |
-
2006
- 2006-06-05 US US11/446,628 patent/US7374924B2/en active Active
-
2007
- 2007-02-01 AU AU2007200434A patent/AU2007200434B2/en active Active
- 2007-05-30 JP JP2009514239A patent/JP4520531B2/ja active Active
- 2007-05-30 MY MYPI20071631A patent/MY162708A/en unknown
- 2007-05-30 KR KR1020107012584A patent/KR101308865B1/ko active Active
- 2007-05-30 CA CA2650546A patent/CA2650546C/en active Active
- 2007-05-30 NZ NZ596788A patent/NZ596788A/xx not_active IP Right Cessation
- 2007-05-30 GE GEAP200711000A patent/GEP20125480B/en unknown
- 2007-05-30 EP EP07748532.4A patent/EP2040722B1/en active Active
- 2007-05-30 UA UAA200813986A patent/UA93911C2/ru unknown
- 2007-05-30 CN CN201110432103.1A patent/CN102488717B/zh active Active
- 2007-05-30 KR KR1020087026182A patent/KR101030661B1/ko active Active
- 2007-05-30 BR BRPI0710944A patent/BRPI0710944B8/pt active IP Right Grant
- 2007-05-30 CN CN2007800012187A patent/CN101374533B/zh active Active
- 2007-05-30 NZ NZ572359A patent/NZ572359A/en unknown
- 2007-05-30 DK DK07748532.4T patent/DK2040722T3/en active
- 2007-05-30 SI SI200731741T patent/SI2040722T1/sl unknown
- 2007-05-30 MX MX2008014869A patent/MX2008014869A/es active IP Right Grant
- 2007-05-30 HU HUE07748532A patent/HUE026416T2/en unknown
- 2007-05-30 RU RU2008147883/10A patent/RU2435844C2/ru active
- 2007-05-30 WO PCT/SE2007/050371 patent/WO2007142596A1/en not_active Ceased
- 2007-05-30 ZA ZA200809531A patent/ZA200809531B/xx unknown
- 2007-10-29 US US11/978,417 patent/US9057112B2/en active Active
-
2008
- 2008-10-22 IL IL194779A patent/IL194779A0/en active IP Right Grant
-
2010
- 2010-04-14 JP JP2010092728A patent/JP2010202654A/ja active Pending
- 2010-07-14 AU AU2010202976A patent/AU2010202976B2/en active Active
-
2012
- 2012-01-23 US US13/355,585 patent/US9340840B2/en active Active
-
2013
- 2013-03-27 JP JP2013065540A patent/JP5865283B2/ja active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040185032A1 (en) | 2003-03-18 | 2004-09-23 | David Burrell | Compositions and methods for treating colic |
| US20050271641A1 (en) | 2004-06-03 | 2005-12-08 | Bengt Bjorksten | Method for improved breast milk feeding to reduce the risk of allergy |
Non-Patent Citations (2)
| Title |
|---|
| Pediatric Research, Vol.58, pp.411 (2005.08.) * |
| Pediatric Research, Vol.58, pp.411 (2005.08.)* |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101308865B1 (ko) | 유아 산통을 감소시키기 위한 선별된 유산균의 용도 | |
| CN100552016C (zh) | 用于治疗炎性疾病的双歧杆菌 | |
| EP2114423B1 (en) | Product containing inactivated probiotic for infants | |
| EP2295535A1 (en) | Probiotic material | |
| EP1868596B1 (en) | Use of lactobacillus rhamnosus gg in combination with a long chain polyunsaturated fatty acid for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant | |
| EP1871401A1 (en) | Use of lactobacillus rhamnosus gg for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant | |
| TWI351962B (en) | Use of selected lactic acid bacteria for reducing | |
| AU2013201542A1 (en) | Use of selected lactic acid bacteria for reducing infantile colic | |
| HK1173944A (en) | Use of selected lactic acid bacteria for reducing infantile colic | |
| HK1125840B (en) | Use of selected lactic acid bacteria for reducing infantile colic | |
| HK1173944B (en) | Use of selected lactic acid bacteria for reducing infantile colic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20100608 Application number text: 1020087026182 Filing date: 20081027 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20110908 Comment text: Request for Examination of Application |
|
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20120119 Patent event code: PE09021S01D |
|
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20120828 Patent event code: PE09021S01D |
|
| PE0902 | Notice of grounds for rejection |
Comment text: Final Notice of Reason for Refusal Patent event date: 20130306 Patent event code: PE09021S02D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20130823 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20130909 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20130909 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| FPAY | Annual fee payment |
Payment date: 20160816 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20160816 Start annual number: 4 End annual number: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20170615 Year of fee payment: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20170615 Start annual number: 5 End annual number: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20180622 Year of fee payment: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20180622 Start annual number: 6 End annual number: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20190814 Year of fee payment: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20190814 Start annual number: 7 End annual number: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20200813 Start annual number: 8 End annual number: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20210830 Start annual number: 9 End annual number: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 20220812 Start annual number: 10 End annual number: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 20240812 Start annual number: 12 End annual number: 12 |